Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Investigator: Eleni Efstathiou, MD

Study Coordinator: Gabrielle Hayes

Status: Open Not Enrolling Number: NCT03574571

Phone: 734.419.948

Protocol Number: Pro00022762


The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.
More to Explore